Core Points - A shareholder has filed a securities class action lawsuit against Alto Neuroscience, Inc. on behalf of investors who purchased or acquired the company's common stock during its IPO on February 2, 2024, and between February 2, 2024, and October 22, 2024 [1][2] Summary by Sections Lawsuit Details - The lawsuit alleges that the defendants made misrepresentations regarding the clinical, regulatory, and commercial prospects of ALTO-100, a drug aimed at treating major depressive disorder [2] Lead Plaintiff Information - Interested parties wishing to serve as lead plaintiff must file necessary documents by September 19, 2025, and participation as a lead plaintiff is not required to share in any potential recovery [3] Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4]

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Allegations and Misleading Information - The Offering Documents related to the IPO were claimed to be negligently prepared, leading to misinformation about ALTO-100's effectiveness in treating major depressive disorder (MDD) [2]. - It was alleged that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, which in turn inflated Alto's business and financial outlook [2]. Group 2: Clinical Trial Results and Stock Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial for MDD, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS) [3]. - Following this announcement, Alto's stock price plummeted by $10.17 per share, representing a 69.99% decline, closing at $4.36 per share on October 23, 2024 [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 4: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the company's product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - The complaint against Alto alleges violations of federal securities laws due to misleading statements regarding the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) and the overstated prospects of the company's business and financial performance [2]. Group 1: Company Performance and Stock Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for MDD, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 on October 23, 2024 [3]. - Following the announcement, Jeffries reduced its price target for Alto from $33 to $17, indicating concerns about the company's biomarker approach to central nervous system disorders and psychiatry [4]. Group 2: Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [5]. - The law firm Faruqi & Faruqi encourages individuals with information regarding Alto's conduct to come forward, including whistleblowers and former employees [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and its effectiveness in treating major depressive disorder [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all persons and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although this is not required to partake in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will be enrolled in a portfolio monitoring software for updates on the case [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [6].

For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-41944 _________________________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Alto Neuroscience, Inc. (Exact name of registrant a ...

Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO- 207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet Psychiatry – – ALTO-207 adds expected late-stage readout in treatment resistant depression within current cash runway; planned Phase 2b trial, designed to be a potentially pivotal study e ...

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) due to allegations of misleading statements regarding the effectiveness of its product pipeline, ALTO-100 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that during the class period, the defendants made materially false and misleading statements about ALTO-100's effectiveness in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [2]. - As a result of these misleading statements, Alto's business and financial prospects were also overstated, leading to a misrepresentation of the company's public statements [2]. Group 2: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [1]. - Shareholders are encouraged to register for the class action by September 19, 2025, to participate in potential recovery [3]. Group 3: Law Firm's Commitment - The Gross Law Firm is dedicated to protecting the rights of investors who have suffered losses due to deceit and illegal business practices, aiming to ensure companies adhere to responsible business practices [4].